Literature DB >> 26357792

Factor XII Deficiency and Cardiopulmonary Bypass.

Victor Uppal, Mark Rosin.   

Abstract

Factor XII deficiency is a laboratory finding in patients who normally do not present with bleeding tendencies. This deficiency is important in the patient undergoing cardiopulmonary bypass because activated clotting times are not helpful in determining proper levels of heparin anticoagulation and its reversal. We present a case of a patient with factor XII deficiency that had coronary artery bypass grafting and cardiopulmonary bypass using heparin for anticoagulation. Cardiopulmonary bypass was successfully carried out by monitoring heparin concentration ensuring adequate heparinization during the procedure. Results from activated clotting time, heparin dose-response, and heparin protamine titration are given. Heparin anticoagulation in patients with factor XII deficiency can be safely carried out with heparin concentration monitoring.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 26357792      PMCID: PMC4566835     

Source DB:  PubMed          Journal:  J Extra Corpor Technol        ISSN: 0022-1058


  13 in total

1.  Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.

Authors:  Andreas Koster; Thomas Fischer; Michael Praus; Helmut Haberzettl; Wolfgang M Kuebler; Roland Hetzer; Herman Kuppe
Journal:  Anesthesiology       Date:  2002-10       Impact factor: 7.892

2.  Activated clotting time (ACT).

Authors:  Stephen Horton; Simon Augustin
Journal:  Methods Mol Biol       Date:  2013

Review 3.  Structural and functional characterization of factor XII.

Authors:  G Tans; J Rosing
Journal:  Semin Thromb Hemost       Date:  1987-01       Impact factor: 4.180

4.  Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency.

Authors:  R M Moorman; D S Reynolds; M E Comunale
Journal:  J Cardiothorac Vasc Anesth       Date:  1993-08       Impact factor: 2.628

5.  Congenital factor XII deficiency and cardiopulmonary bypass.

Authors:  M K Wood
Journal:  Ann Thorac Surg       Date:  1994-11       Impact factor: 4.330

6.  Biological stress induced by extracorporeal circulation: comparison between cardiopulmonary bypass, hemodialysis and plasma exchange.

Authors:  P Stratta; C Canavese; P Costa; C Martini; T Festa; A Bulla; A Vercellone
Journal:  Trans Am Soc Artif Intern Organs       Date:  1984

7.  Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients.

Authors:  G J Despotis; K S Filos; T N Zoys; C W Hogue; E Spitznagel; D G Lappas
Journal:  Anesth Analg       Date:  1996-01       Impact factor: 5.108

8.  Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery.

Authors:  K Tanaka; M Takao; I Yada; H Yuasa; M Kusagawa; K Deguchi
Journal:  J Cardiothorac Anesth       Date:  1989-04

9.  The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors.

Authors:  W M Halbmayer; A Haushofer; R Schön; C Mannhalter; E Strohmer; K Baumgarten; M Fischer
Journal:  Thromb Haemost       Date:  1994-01       Impact factor: 5.249

10.  Factor XII deficiency and cardiopulmonary bypass.

Authors:  M Wallock; C Arentzen; J Perkins
Journal:  Perfusion       Date:  1995       Impact factor: 1.972

View more
  2 in total

1.  Aortic valve replacement and ventricular septal defect repair in factor XII deficiency: An anesthetic challenge.

Authors:  Swapnil Verma; U Srinivas; A K Sathpathy; Priyanka Mittal
Journal:  Saudi J Anaesth       Date:  2019 Jan-Mar

2.  Global cerebral infarction after aortic arch replacement surgery in a patient with postoperatively revealed factor XII deficiency: a case report.

Authors:  Keisuke Yoshida; Shiori Tanaka; Yuki Sato; Kazuhiro Watanabe; Kenichi Muramatsu; Masahiro Murakawa
Journal:  J Med Case Rep       Date:  2020-09-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.